These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 10482907)

  • 41. A potential important role for thymidylate synthetase inhibition on antitumor activity of fluoropyrimidine and raltitexed.
    Kabeshima Y; Kubota T; Watanabe M; Saikawa Y; Nishibori H; Hasegawa H; Kitajima M
    Anticancer Res; 2002; 22(6A):3245-52. PubMed ID: 12530071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancement of 5-fluorouracil sensitivity by an rTS signaling mimic in H630 colon cancer cells.
    Dolnick R; Wu Q; Angelino NJ; Stephanie LV; Chow KC; Sufrin JR; Dolnick BJ
    Cancer Res; 2005 Jul; 65(13):5917-24. PubMed ID: 15994970
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
    Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
    Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interaction of tomudex with radiation in vitro and in vivo.
    Teicher BA; Ara G; Chen YN; Recht A; Coleman CN
    Int J Oncol; 1998 Sep; 13(3):437-42. PubMed ID: 9683775
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Biochemical modulation of iododeoxyuridine by N6-[4-(morpholinosulfonyl)benzyl]-N6-methyl-2,6-diaminobenz[cd]indole glucuronate (AG-331) leading to enhanced cytotoxicity.
    Pressacco J; Mitrovski B; Hedley DW; Tsang R; Erlichman C
    Biochem Pharmacol; 1995 Jun; 50(1):55-60. PubMed ID: 7605345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression.
    Pressacco J; Mitrovski B; Erlichman C; Hedley DW
    Cancer Res; 1995 Apr; 55(7):1505-8. PubMed ID: 7882359
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors.
    Van Triest B; Pinedo HM; Giaccone G; Peters GJ
    Ann Oncol; 2000 Apr; 11(4):385-91. PubMed ID: 10847455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The interaction of thymidylate synthase expression with p53-regulated signaling pathways in tumor cells.
    Longley DB; Latif T; Boyer J; Allen WL; Maxwell PJ; Johnston PG
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):3-9. PubMed ID: 12802789
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer.
    Xi Y; Nakajima G; Schmitz JC; Chu E; Ju J
    BMC Genomics; 2006 Apr; 7():68. PubMed ID: 16584549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Creation and characterization of 5-fluorodeoxyuridine-resistant Arg50 loop mutants of human thymidylate synthase.
    Landis DM; Heindel CC; Loeb LA
    Cancer Res; 2001 Jan; 61(2):666-72. PubMed ID: 11212266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
    Yeh KH; Yeh SH; Hsu CH; Wang TM; Ma IF; Cheng AL
    Br J Cancer; 2000 Dec; 83(11):1510-5. PubMed ID: 11076661
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
    Ward WH; Kimbell R; Jackman AL
    Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thymidylate synthase inhibitors.
    Touroutoglou N; Pazdur R
    Clin Cancer Res; 1996 Feb; 2(2):227-43. PubMed ID: 9816165
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
    Nagasaki T; Tsuchiya T; Tagawa T; Honda S; Yamasaki N; Miyazaki T; Hidaka S; Hayashi T; Nagayasu T
    Clin Lung Cancer; 2010 Nov; 11(6):412-22. PubMed ID: 21062732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Isolation and characterization of a human ileocecal carcinoma cell line (HCT-8) subclone resistant to fluorodeoxyuridine.
    Zhang ZG; Malmberg M; Yin MB; Slocum HK; Rustum YM
    Biochem Pharmacol; 1993 Mar; 45(5):1157-64. PubMed ID: 8461045
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
    Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
    Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
    Takagi K; Sowa Y; Cevik OM; Nakanishi R; Sakai T
    Int J Oncol; 2008 May; 32(5):1105-10. PubMed ID: 18425338
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Thymidylate synthase: a critical target for cancer chemotherapy.
    Rose MG; Farrell MP; Schmitz JC
    Clin Colorectal Cancer; 2002 Feb; 1(4):220-9. PubMed ID: 12450420
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism.
    Peters GJ; Backus HH; Freemantle S; van Triest B; Codacci-Pisanelli G; van der Wilt CL; Smid K; Lunec J; Calvert AH; Marsh S; McLeod HL; Bloemena E; Meijer S; Jansen G; van Groeningen CJ; Pinedo HM
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):194-205. PubMed ID: 12084461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma.
    Flynn J; Berg RW; Wong T; van Aken M; Vincent MD; Fukushima M; Koropatnick J
    Mol Cancer Ther; 2006 Jun; 5(6):1423-33. PubMed ID: 16818500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.